Stay updated on market trends for XLO. Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? AbbVie and Xilio partner to develop tumor-activated immunotherapies.

Shares in biotech group Xilio Therapeutics (XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie Inc. (ABBV). The two companies announced a collaboration and option-to ...

Short interest in Xilio Therapeutics Inc (NASDAQ:XLO) decreased during the last reporting period, falling from 694.61K to 575.45K. This put 1.3% of the company's publicly available shares short.